To realize the future of gene therapy, partners in the Precision Health Alliance will work together to ask scientific questions, consider ethical and regulatory implications, and understand patient and community perspectives.
For more information on Precision Health Alliance partnership, email PrecisionHealthAlliance@dm.duke.edu.
“We are looking forward to partnering with the Precision Health Alliance to find solutions to common challenges that we all are facing in trying to bring an entirely new class of medicines, one that utilizes genome editing for a potential one-time treatment to patients with significant unmet medical needs,”
Amy Simon, M.D.
Beam Therapeutics
“This alliance can help propel genetic medicine to play a greater role in health care, with the goal of helping patients as in vivo gene editing becomes more broadly adopted.”
Julianne Bruno, MBA
CRISPR Therapeutics
“Precision health has the potential to revolutionize the way we prevent, diagnose, and treat disease.”
David Lebwohl, M.D.
Intellia Therapeutics
“It’s important to work together as a collaborative community to ensure these exciting clinical breakthroughs have the greatest benefit for patients.”
Fred T. Fiedorek, M.D.
Verve Therapeutics
